bioMérieux – Critical Care Biomarker Development

bioMérieux is a world leader in the field of in vitro diagnostics for more than 50 years, its development has been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. bioMérieux is global IVD company with sales amounting to €1.588 billion in 2013, among which 87% is done outside of France. Today, bioMérieux provides diagnostics solutions (reagents, instruments, software) in more than 150 countries through 41 subsidiaries and a large network of distributors. bioMérieux is world leader in microbiology and a major player in infectious diseases, through for example high medical value tests in immunology. The Sepsis Joint Unit is dedicated to biomarker discovery and validation in intensive care unit patients and especially sepsis patients. PhD and master students are regularly trained in the Sepsis Joint Unit. Students will have access to a large list of classical and more high tech tools and platforms (microarrays, qRT-PCR, cellular culture facilities, mass spectrometers ESI-MS, multiplex ELISA platforms) together with an adapted biostat and bioinformatics environment.

Involved researchers:

Alexandre Pachot PharmD PhD. Director of Medical Diagnostic Discovery Department. He graduated from Pharmacy university of Lyon in 2002 and has a PhD in immunogenomic since 2005. His work focused on immune response monitoring following sever insults like sepsis or trauma and led to the identification of new relevant biomarkers. After 6 years of experience as clinical research project leader and research lab manager at bioMérieux and Hospices Civils de Lyon (HCL), he joined Sanofi Pasteur as head Head of R&D Immuno-chemistry Platform. Since 2009, he’s been successively Program Director Infectious Diseases & Critical Care at bioMérieux Biomarkers Department, and Director of Diagnostic Discovery Departement, leading a group ~40 researchers and technicians with a large project portfolio in the field of infectious diseases and critical care.

François Mallet PhD. has been developing for several years a research program on endogen retroviruses within bioMérieux and is the creator of a HERV specific microarray. He is recognized as an international expert on HERV.

Julien Textoris, MD, PhD is Co-Director of the Sepsis Joint Unit and will also be involved in the training and supervision of ESRs working of seconded at bioMérieux . He holds a PhD in bioinformatics and studied the host response to injury, mainly through transcriptional analysis and systems biology. He was appointed assistant professor in Immunology in Aix-Marseille school of medicine before joining bioMérieux in February 2014, as head of a joint research unit (~14 people) between bioMérieux and Hospices Civils de Lyon.